Cargando…

Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma

A tight interplay between inflammation and hemostasis has been described as a potential driver for developing venous thromboembolism (VTE). Here, we investigated the association of systemic cytokine levels and risk of VTE in patients with glioma. This analysis was conducted within the prospective, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mir Seyed Nazari, Pegah, Marosi, Christine, Moik, Florian, Riedl, Julia, Özer, Öykü, Berghoff, Anna Sophie, Preusser, Matthias, Hainfellner, Johannes A., Pabinger, Ingrid, Zlabinger, Gerhard J., Ay, Cihan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966639/ https://www.ncbi.nlm.nih.gov/pubmed/31847343 http://dx.doi.org/10.3390/cancers11122020

Ejemplares similares

Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2020)

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
por: Mir Seyed Nazari, P., et al.
Publicado: (2018)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
por: Moik, Florian, et al.
Publicado: (2020)

ABO blood group type and risk of venous thromboembolism in patients with cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

How I treat cancer-associated thrombosis
por: Moik, Florian, et al.
Publicado: (2020)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality
por: Riedl, Julia, et al.
Publicado: (2014)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer
por: Moik, Florian, et al.
Publicado: (2020)

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
por: Bienkowski, Michal, et al.
Publicado: (2015)

Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma
por: Arnold, J M, et al.
Publicado: (2005)

C-C Motif Chemokine Ligand 5 (CCL5) Promotes Irradiation-Evoked Osteoclastogenesis
por: Wang, Jing, et al.
Publicado: (2023)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity
por: Scheu, Stefanie, et al.
Publicado: (2017)

Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer
por: Moik, Florian, et al.
Publicado: (2022)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Genetic Association of the C-C Motif Chemokine Ligand 2 (CCL2) rs1024611 Polymorphism With Periodontitis
por: Ahmed Khan, Hooriyah Laiq, et al.
Publicado: (2023)

Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

CC chemokines CCL2, CCL3, CCL4 and CCL5 are elevated in osteoporosis patients
por: Farangis, Fatehi, et al.
Publicado: (2017)

Variants of C-C Motif Chemokine 22 (CCL22) Are Associated with Susceptibility to Atopic Dermatitis: Case-Control Studies
por: Hirota, Tomomitsu, et al.
Publicado: (2011)

Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications
por: Guan, Ruili, et al.
Publicado: (2011)

Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss
por: Said, Surita Binti, et al.
Publicado: (2020)

Common transcriptional programs and the role of chemokine (C-C motif) ligand 20 (CCL20) in cell migration of cholangiocarcinoma
por: Win Maung, Hay Mar, et al.
Publicado: (2020)

Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State?
por: Dommel, Sebastian, et al.
Publicado: (2021)

Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers
por: Berghoff, Anna S., et al.
Publicado: (2013)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Inhibition of Chemokine (C-C Motif) Receptor 7 Sialylation Suppresses CCL19-Stimulated Proliferation, Invasion and Anti-Anoikis
por: Su, Mei-Lin, et al.
Publicado: (2014)

Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression
por: Kwantwi, Louis Boafo, et al.
Publicado: (2021)

External validation of urinary C–C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury
por: Bagshaw, Sean M., et al.
Publicado: (2021)

Renin angiotensin system molecules and chemokine (C-C motif) ligand 2 (CCL2) in chronic kidney disease patients
por: Schettini, Isabella Viana Gomes, et al.
Publicado: (2021)

Role Of The C-C Motif Chemokine Ligand 5 (CCL5) And Its Receptor, C-C Motif Chemokine Receptor 5 (CCR5) In The Genesis Of Aldosterone-induced Hypertension, Vascular Dysfunction, And End-organ Damage
por: Costa, Rafael M., et al.
Publicado: (2023)

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
por: Bianconi, Daniela, et al.
Publicado: (2015)

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study
por: Ay, Cihan, et al.
Publicado: (2022)

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2018)

Effect of Chemokine (C-C Motif) Ligand 7 (CCL7) and Its Receptor (CCR2) Expression on Colorectal Cancer Behaviors
por: Kurzejamska, Ewa, et al.
Publicado: (2019)

Adipose-specific C-C motif chemokine ligand (CCL) 19 overexpression drives the mice to both insulin resistance and weight gain
por: Hayashi, Masato, et al.
Publicado: (2021)

A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

The Chemokine CCL3 Promotes Experimental Liver Fibrosis in Mice
por: Heinrichs, Daniel, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0fa5u6aak06ckln5puultfms3n